Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 15/20 | 1.00 |
| ▸ | PDK2 | Q15119 | 15/20 | 1.00 |
| ▸ | PDK3 | Q15120 | 15/20 | 1.00 |
| ▸ | PDK4 | Q16654 | 15/20 | 1.00 |
| ▸ | ABCC9 | O60706 | 7/20 | 0.77 |
| ▸ | ABCC8 | Q09428 | 7/20 | 0.77 |
| ▸ | KCNJ11 | Q14654 | 7/20 | 0.77 |
| ▸ | KCNJ8 | Q15842 | 7/20 | 0.77 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.77 |
| ▸ | MEN1 | O00255 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28050469 | 1.00 | PDK1 (1.00) | PDK1PDK2PDK3PDK4ABCC9 | |
| Zd-6169 SCHEMBL2123811 | 0.87 | ABCC9 (1.00) | PDK1PDK2PDK3PDK4ABCC9 | |
| Zd-6169 SCHEMBL4261046 | 0.87 | ABCC9 (1.00) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL2128828 | 0.85 | ABCC9 (1.00) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL5317709 | 0.84 | PDK1 (0.75) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL8489691 | 0.84 | ABCC9 (0.74) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL9709058 | 0.83 | PDK1 (0.71) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL16212234 | 0.82 | PDK1 (0.70) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL8867579 | 0.81 | PDK1 (0.71) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL3129785 | 0.80 | PDK1 (0.67) | PDK1PDK2PDK3PDK4ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103951584-B | Derivative of 3-chloro-N-phenyl-4-(the fluoro-2-methyl of 3,3,3-tri--2-hydroxypropanamide base) benzamide and preparation method thereof and application | TSINGHUA UNIVERSITY (CN) | 2016-02-10 | — | — | CN | disclosed |
| CN-101328157-A | Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | CN | disclosed |
| CN-1235877-C | Substd. N-phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. which elevate pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2006-01-11 | — | — | CN | disclosed |
| US-20050026931-A1 | Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2005-02-03 | — | — | US | disclosed |
| CN-1387509-A | Substd. N-phenyl-2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivs. which elevate pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-25 | — | — | CN | disclosed |
| EP-1214296-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2002-06-19 | — | — | EP | disclosed |
| WO-2002004598-A2 | IMPROVEMENT OF CELL CULTURE PERFORMANCE BY INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE | IMMUNEX CORPORATION (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001017956-A1 | SUBSTITUTED N-PHENYL 2-HYDROXY-2-METHYL-3,3,3-TRIFLUOROPROPANAMIDE DERIVATIVES WHICH ELEVATE PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026931-A1 | Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluropropanamide derivatives which elevate pyruvate dehydrogenase activity | PDHA1, PDHA2, PDHB | PDK1 4/4885PDK2 5/4885PDK3 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.